Company Encyclopedia
View More
name
TNF Pharmaceuticals
TNFA.US
TNF Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, focuses on developing and commercializing therapeutic platforms based on various therapeutic targets. The company develops Isomyosamine, a clinical stage small molecule that regulates the immunometabolic system to treat autoimmune disease, including sarcopenia, frailty, adverse effects of drugs used to treat diabetes and obesity, rheumatoid arthritis, and inflammatory bowel disease. It also develops Supera-CBD, a synthetic analog of derivative of cannabidiol (CBD) to treat various conditions, including epilepsy, pain and anxiety/depression. The company has a strategic alliance with DADA2 Foundation for research into the rare inflammatory disease DADA2 (Deficiency of Adenosine Deaminase 2).
4.361 T
TNFA.USMarket value -Rank by Market Cap -/-

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    TNF Pharmaceuticals Rebrands to Q/C Technologies

    TNF Pharmaceuticals has rebranded to Q/C Technologies as of September 22, 2025, reflecting its strategic shift towards quantum-class computing. The company’s stock now trades under the ticker symbol ‘QCLS’ on the Nasdaq. This change aligns with its focus on photonic computing and exclusive rights to LightSolver’s platform, enhancing its market position. Q/C Technologies operates in high-performance computing, particularly in quantum-class cryptocurrency applications, with a current market cap of $9.29M and an average trading volume of 1,611,301.

    Tip Ranks·
    US
    TNFA
    0.00%
    Tip Ranks·
    US
    TNFA
    0.00%

    TNF Pharmaceuticals Announces Name Change to Q/C Technologies and New Ticker Symbol “QCLS” to Reflect Strategic Focus on Quantum Class Photonic Computing | TNFA Stock News

    TNF Pharmaceuticals has changed its name to Q/C Technologies and will trade under the new ticker symbol "QCLS" starting September 25, 2025. This rebranding reflects the company's strategic focus on quantum-class computing, particularly in the cryptocurrency sector, leveraging exclusive rights to LightSolver's laser processing technology. The new technology promises significant energy savings and enhanced security for blockchain operations. Current shareholders do not need to take any action regarding the name and symbol change, and the company continues to explore options for its legacy therapeutic programs.

    StockTitan·
    US
    TNFA
    0.00%
    US
    QCLS
    +1.23%
    StockTitan·
    US
    TNFA
    0.00%
    US
    QCLS
    +1.23%

    TNF Pharmaceuticals Inc. Regains Compliance with Nasdaq Minimum Bid Price Rule

    TNF Pharmaceuticals Inc. has regained compliance with Nasdaq's minimum bid price requirement, confirmed on September 16, 2025. The company maintained a minimum bid price of $1.00 for 10 consecutive business days, meeting Nasdaq Listing Rule 5550 (a)(2). Executive Chairman Joshua Silverman expressed satisfaction with this achievement and emphasized the company's focus on growth and enhancing shareholder value, with further updates expected soon.

    Reuters·
    US
    TNFA
    0.00%
    US
    QCLS
    +1.23%
    Reuters·
    US
    TNFA
    0.00%
    US
    QCLS
    +1.23%

    TNF Pharmaceuticals Secures $7M in Private Placement

    TNF Pharmaceuticals has closed a $7 million private placement financing of convertible preferred stock with its largest strategic stockholder and other existing stockholders. This financing, priced at a 44% premium to market, will support the company's development of light-based computing accelerator technology for blockchain. The company also issued Series H and I Convertible Preferred Stock and amended terms for Series F and F-1, extending maturity dates and removing amortization payments. TNF Pharmaceuticals focuses on innovative technologies and pharmaceutical candidates, with a current market cap of $6.73M.

    Tip Ranks·
    US
    TNFA
    0.00%
    US
    QCLS
    +1.23%
    Tip Ranks·
    US
    TNFA
    0.00%
    US
    QCLS
    +1.23%

    12 Health Care Stocks Moving In Tuesday's After-Market Session

    In Tuesday's after-market session, several health care stocks saw significant movements. Revelation Biosciences (REVB) gained 7.7% to $2.51, with a market value of $4.7 million. Nautilus Biotechnology (NAUT) rose 7.47% to $0.72, valued at $88.0 million. Ernexa Therapeutics (ERNA) increased 7.37% to $1.36, with a market cap of $9.1 million. Kura Oncology (KURA) saw a 6.99% rise to $8.57, valued at $706.5 million. Jin Medical International (ZJYL) rose 5.95% to $0.68, with a market value of $98.6 million, and TNF Pharmaceuticals (TNFA) increased 5.88% to $3.78, valued at $6.7 million.

    Benzinga·
    US
    KURA
    -3.00%
    Benzinga·
    US
    KURA
    -3.00%